THIS CENTURY, THE BIRTHS OF SOME 200 MILLION PEOPLE WILL BE THE RESULT OF IVF. TMRW IS HERE TO PROTECT EACH AND EVERY ONE.
Today, one in 20 Japanese children is born via in vitro fertilization. In Norway, that number is one in 10. By the end of this century, more than 200 million people worldwide will be born as a result of IVF.
Today, nearly 100% of the eggs and embryos acquired for IVF will be vitrified (frozen extremely quickly) and cryopreserved at -190 degrees celsius. This process—a medical breakthrough only recently adopted for widespread use—enables reproductive cells to be viable over very long periods of time.
Cryopreservation requires faultless short- and long-term cryostorage. Cryostorage contributes to the improvements of patient outcomes in a number of ways including helping to eliminate multiple-gestation pregnancies, facilitating genetic testing, and providing would-be parents more control over their reproductive planning.
TMRW IS THE WORLD’S FIRST TECH-ENABLED, AUTOMATED CRYOSTORAGE PLATFORM.
Developed in partnership with leading fertility doctors and embryologists, TMRW’s technology significantly reduces risk to the precious and fragile cells and tissues used in IVF. Our robotic process automation radically improves the identification, freezing and storage of reproductive cells and embryos—putting an end to the error-prone manual and analog methods that have gone unchanged since IVF was first used in animal husbandry more than fifty years ago. Our automation eliminates 20% of the time required to perform manual tasks in the embryology lab, allowing embryologists to focus on the most skilled and technical aspects of their work.
TMRW provides a 100% digital chain of custody. This includes continuous local and remote electronic monitoring with integrated processes producing 10,000 daily digital signals which are used to constantly monitor, maintain and safeguard the integrity and security of the reproductive cells in our care.
As requested by our physician partners, the TMRW platform is designed for both in-clinic and remote storage.
The TMRW team includes many of the world’s most celebrated pioneers in clinical medicine, reproductive biology and embryology, vitrification, and cryogenic biobanking who have synthesized their collective knowledge, vision and experience in the development of the TMRW system.
Our founders have started both data science and medical firms, the most recent of which have been acquired for a combined exit value in excess of $1 billion.